X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/quralis-to-present-data-showing-link-between-tdp-43-pathology-and-role-of-unc13a-in-neuronal-biology-related-to-als-and-other-neurodegenerative-diseases-301917970.html
https://www.fiercebiotech.com/cro/quralis-links-unlearn-leverage-machine-learning-als-research
https://www.prnewswire.com/news-releases/quralis-flexasos-show-high-potency-and-improved-safety-over-standard-asos-301844579.html
https://www.clinicaltrialsarena.com/news/quralis-authorisation-als-therapy-eu/
https://www.prnewswire.com/news-releases/quralis-receives-clinical-trial-authorisation-cta-in-european-union-eu-for-qrl-201-a-first-in-class-stathmin-2-precision-therapy-for-als-301839151.html
https://www.prnewswire.com/news-releases/quralis-to-participate-in-upcoming-investor-conferences-in-june-301839153.html
https://www.clinicaltrialsarena.com/news/news-quralis-phase-i-trial-als/
https://www.prnewswire.com/news-releases/quralis-reveals-newest-program-targeting-unc13a-rna-mis-splicing-incorporating-its-flexaso-platform-301775891.html
https://endpts.com/als-biotech-quralis-gets-88m-boost-from-4-pharmas-for-pair-of-phi-studies/
https://www.prnewswire.com/news-releases/quralis-closes-88-million-series-b-financing-to-advance-precision-medicines-for-neurodegenerative-diseases-301765435.html
Market Place
Share 
